Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clostridium difficile toxoids A and B
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Clostridium difficile toxoids A and B are inactivated (non-toxic) forms of the two major toxins produced by Clostridium difficile—Toxin A (an enterotoxin) and Toxin B (a cytotoxin). These purified antigens are generated by treating the native toxins with formaldehyde to eliminate toxicity while preserving antigenicity[1][4][5]. The primary use of these toxoids is as immunogens for raising antibodies or as components in vaccine development against C. difficile infection[1][4][6]. They may also be used in diagnostic assays to detect immune responses or toxin exposure[4][5]. The mechanism of action for vaccines based on these antigens is to stimulate an immune response that neutralizes the pathogenic effects of Toxins A and B, thereby preventing or reducing disease severity caused by C. difficile infection[6].
- Other names
- C. difficile toxoid AC. difficile toxoid BClostridioides difficile toxoids A and B
02
Targets
TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on Clostridium difficile toxoids A and B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clostridium difficile toxoids A and B.